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Aging elicits quantitative and qualitative changes in different
immune components, leading to disruption of tolerogenic circuits
and development of autoimmune disorders. Galectin-1 (Gal1), an
endogenous glycan-binding protein, has emerged as a regulator of
immune cell homeostasis by shaping the fate of myeloid and
lymphoid cells. Here, we demonstrate that aged Gal1-null mutant
(Lgals1−/−) mice develop a spontaneous inflammatory process in
salivary glands that resembles Sjögren’s syndrome. This spontane-
ous autoimmune phenotype was recapitulated in mice lacking
β1,6N-acetylglucosaminyltransferase V (Mgat5), an enzyme re-
sponsible for generating β1,6-branched complex N-glycans, which
serve as a major ligand for this lectin. Lack of Gal1 resulted in
CD11c+ dendritic cells (DCs) with higher immunogenic potential,
lower frequency of Foxp3+ regulatory T cells (Tregs), and increased
number of CD8+ T cells with greater effector capacity. Supporting
its tolerogenic activity, Gal1 expression decreased with age in
autoimmunity-prone nonobese diabetic (NOD) mice. Treatment
with recombinant Gal1 restored tolerogenic mechanisms and re-
duced salivary gland inflammation. Accordingly, labial biopsies
from primary Sjögren’s syndrome patients showed reduced Gal1
expression concomitant with higher number of infiltrating CD8+
T cells. Thus, endogenous Gal1 serves as a homeostatic rheostat
that safeguards immune tolerance and prevents age-dependent
development of spontaneous autoimmunity.
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Immune tolerance relies on regulatory circuits responsible foravoiding autoimmune reactions and dampening exacerbated
immune responses to prevent tissue damage. These homeostatic
mechanisms require the interplay of immune cell mediators pro-
moting contraction of innate and adaptive immune compartments
after the completion of immune responses (1). However, the
presence of self-reactive immune cells within the lymphocyte
repertoire entails an intrinsic potential of triggering autoimmune
reactions, whose development and perpetuation will depend on
genetic and environmental cues leading to disruption of regulatory
networks and breakdown of immune tolerance (1, 2).
The mechanisms responsible for sustaining peripheral T-cell
tolerance involve the expression and activation of several regula-
tory pathways, including coinhibitory receptors and ligands, so-
called immune checkpoints (i.e., CTLA-4/ B7.1-B7.2; PD-1/PD-L1;
BTLA/ HVEM), lineage-specific transcription factors (i.e., Foxp3),
and immunoregulatory cytokines (i.e., IL-10, TGF-β1). The use of
genetically modified mouse strains has provided important clues
on the critical role of these regulatory networks in safeguarding
immune tolerance and preventing autoimmune diseases. In fact,
lack of key immune silencers such as CTLA-4, Foxp3, and TGFβ1
led to severe lymphoproliferative disorders with major infiltration
of central organs and death within the first weeks of age (3–5).
However, other central tolerogenic pathways including those in-
volving PD-1 and BTLA showed a more restricted regulatory
function and may be categorized as rheostats of immune responses
since their deficiency leads to age-dependent tissue-specific im-
munopathology (6–8).
Galectins have emerged as a family of soluble glycan-binding
proteins capable of regulating a broad range of biological pro-
cesses. They are defined by a common structural fold and a
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highly conserved carbohydrate recognition domain (CRD) (9).
These endogenous lectins are synthesized as cytosolic proteins
and can be secreted to the extracellular milieu through a non-
conventional endoplasmic reticulum (ER)-Golgi–independent
route (10). Galectin-1 (Gal1), a prototype member of this family,
has emerged as a regulator of immune cell homeostasis (11, 12).
Extracellularly, this lectin acts by recognizing N-acetyllactosamine
(LacNAc) residues in complex N-glycans and core 2-O-glycans on
a variety of cell surface receptors including CD45, CD43, and CD7
(13). In vivo administration of recombinant Gal1 or its genetic
delivery suppressed clinical manifestations of autoimmune in-
flammation in several models including experimental autoimmune
encephalomyelitis (14, 15), collagen-induced arthritis (16), Con A-
induced hepatitis (17), trinitrobenzene sulfonic acid (TNBS)-
induced colitis (18), nephrotoxic serum nephritis (19), experi-
mental autoimmune uveitis (20), autoimmune diabetes (21), and
autoimmune orchitis (22). The proposed mechanisms underlying
these immunomodulatory effects include a bias toward Th2 cy-
tokine production (16, 20), expansion of regulatory T cells (Tregs)
(20), apoptosis of activated Th1 and Th17 effector cells (14, 23–
25), differentiation of tolerogenic dendritic cells (DCs) (26), ex-
posure of phosphatidylserine in neutrophils leading to their re-
moval by phagocytes (27), and polarization of macrophages and
microglia toward an M2 phenotype (28, 29). Accordingly, mice
lacking Gal1 (Lgals1−/−) displayed enhanced T-cell activation and
increased tissue damage in established models of autoimmune
encephalomyelitis, arthritis, and lupus-like disease (14, 29–31).
However, despite considerable progress, the immunological con-
sequences of disrupting endogenous Gal1 have not been explored
in nonprone nonimmunized mice.
Sjögren’s syndrome is among the most frequent systemic au-
toimmune diseases, affecting primarily women, with an estimated
prevalence of 0.1–4.8% of the population (32). This systemic au-
toimmune disease affects mainly exocrine glands and is usually
associated with persistent oral and ocular dryness due to func-
tional damage of affected organs. Sjögren’s syndrome can occur as
primary disease (i.e., pSS) with clinical manifestations ranging
from sicca symptoms to extraglandular systemic signs or can be
associated to other autoimmune diseases such as systemic lupus
erythematosus (SLE) and rheumatoid arthritis (secondary Sjögren’s
syndrome; sSS) (32, 33). This autoimmune exocrinopathy is char-
acterized by focal lymphocytic infiltration and the presence of
several autoantibodies including antinuclear antibodies (ANA),
rheumatoid factor, and antibodies recognizing Ro/SSA and/or La/
SSB (33–37). Thus far, the etiopathogenic mechanisms of Sjögren’s
syndrome have not been fully elucidated.
In the present study, we analyzed the hierarchical role of Gal1
and specific N-glycans in the development of spontaneous auto-
immunity and evaluated central pathways underlying this immu-
nological phenotype. Aged Lgals1−/−mice developed a spontaneous
inflammatory disorder that recapitulated human Sjögren’s syn-
drome via the coordinated amplification of both innate and adap-
tive immune pathways. This effect was mirrored in aged Mgat5−/−
mice lacking complex branched N-glycans, which serve as major
Gal1 ligands. Supporting these findings, we found a negative as-
sociation between Gal1 expression and infiltration of CD8+ T cells
in labial biopsies from patients with primary Sjögren’s syndrome.
Thus, loss of Gal1 disrupts tolerogenic circuits, leading to a
gradual breakdown of immune tolerance mechanisms and estab-
lishment of age-related spontaneous autoimmunity, highlighting
the relevance of this endogenous lectin as a possible therapeutic
agent in autoimmune diseases.
Results
Disruption of Gal1 Expression or N-Glycan Branching Leads to the
Development of Spontaneous Sialadenitis. Since aging confers in-
creased susceptibility to development of autoimmune diseases,
we studied the role of Gal1 in the control of immune tolerance in
aged (≥9 mo old) Lgals1−/− mice. We first determined the pres-
ence of autoantibodies in serum samples and the composition of
immune cell infiltrates in several tissues and organs. We found
that aged Lgals1−/− mice show increased levels of anti-dsDNA,
anti-nuclear (ANA), and anti-Ro/SSA autoantibodies when com-
pared to age-matched wild-type (WT) mice (Fig. 1A). Moreover,
serum samples of aged Lgals1−/− mice showed increased reactivity
against nuclear structures in HEp-2 cells, with a homogenous and
dense speckled pattern consistent with that triggered by anti-
DNA, anti-Ro/SSA, and anti-La/SSB autoantibodies (Fig. 1B).
The presence of autoantibodies suggests the possibility that au-
toimmune inflammatory processes may occur in particular tissues
and organs. Histopathological assessment revealed the presence of
conspicuous mononuclear cell infiltration in salivary glands of
aged Lgals1−/− mice. The magnitude of histopathological signs was
determined following Chisholm and Mason’s criteria (38). We
found that Lgals1−/− mice displayed increased inflammatory score
compared to WT counterparts (Fig. 1C). The increased inflam-
matory process was associated with elevated salivary gland weight
and alterations of the tissue architecture, evidenced by the loss of
acinar area with an increased number of ducts per unit area (Fig. 1
D and E). Next, we examined the composition of the immune cell
infiltrates in the salivary gland and found that Lgals1−/− mice had
an increased percentage of CD45+ infiltrating leukocytes with a
significant rise in the frequency of CD3+CD8+ T cells as com-
pared to WT mice (Fig. 1F). However, we found no significant
differences in the frequency of CD3+CD4+ T cells or B220+ B
cells (Fig. 1F). Histopathological analysis of other tissues and or-
gans including kidney, skin, stomach, retina, thyroid gland, pan-
creas, liver, and uterus revealed no significant alterations in the
magnitude of immune cell infiltration as compared to aged C57BL/
6 WT mice (SI Appendix, Fig. S1).
N-acetyllactosamine residues present in complex N-glycans
serve as major ligands for Gal1. In particular, the enzyme β1,6 N-
acetylglucosaminyltransferase 5 (Mgat5), which catalyzes the syn-
thesis of β1,6 N-acetylglucosamine branched N-glycans, is central
for the biosynthesis of Gal1 ligands. To gain a more integrated
picture of the role of Gal1–glycan interactions during aging, we
analyzed the presence of salivary gland inflammation in Mgat5−/−
mice and found that, similar to Lgals1−/− mice, agedMgat5−/− mice
displayed augmented inflammatory scores, increased salivary gland
weight, and altered glandular structure (Fig. 2 A–C). Consistent
with these findings, salivary glands fromMgat5−/−mice also showed
higher infiltration of CD45+ cells. Interestingly, these mice showed
a significant increase in all of the three lymphocyte populations
analyzed (Fig. 2D). Thus, deficiency in Gal1 or specific glycosylated
ligands leads to the development of an inflammatory autoimmune
process that affects salivary glands and resembles Sjögren’s syn-
drome in humans.
Lgals1−/− Mice Display Augmented CD8+ T Cell Function in Salivary
Glands. To better understand the cellular components underlying
salivary gland inflammation in aged Lgals1−/− mice, we immu-
nophenotyped infiltrating CD8+ T cells and found a greater pro-
portion of CD8+IL-2+IFN-γ+ and CD8+IFN-γ+ cells in salivary
glands from aged Lgals1−/− compared to control mice (Fig. 3A),
suggesting a role for Gal1 in regulating the effector function of
infiltrating CD8+ T cells. In addition, we found a higher percentage
of CD8+PD-1+ lymphocytes in the salivary glands of Lgals1−/−
versus WT mice (Fig. 3B). To investigate whether Gal1 deficiency
impacts the integrity of the PD-1/PD-L1 axis, we then analyzed
expression of the coinhibitory ligand PD-L1 in salivary glands. We
found that aged Lgals1−/− mice expressed significantly lower levels
of PD-L1 than age-matched WTmice (Fig. 3C), suggesting that, in
the absence of Gal1, CD8+PD-1+ cells would meet a less in-
hibitory milieu within the salivary gland. To gain further insight
into the mechanisms involved in tissue infiltration and damage,
we evaluated the expression of chemokines and chemokine











































receptors responsible for recruiting CD8+ effector T cells to
salivary glands. We found that salivary glands from aged Lgals1−/−
mice displayed higher Cxcl9 and Cxcl10 mRNA expression in
comparison to salivary glands from age-matched WT mice (Fig.
3D). Consistent with these findings, submandibular lymph nodes
(SLNs) from aged Lgals1−/− mice showed an increased frequency
of total CD8+ and CD8+CXCR3+ T cells (Fig. 3E), suggesting
that CD8+ effector T cells can be actively recruited to this target
organ. Likewise, agedMgat5−/−mice displayed a significantly higher
proportion of CD3+CD8+ T cells and a trend toward an increase of
CD8+CXCR3+ T cells in SLN compared to WT mice (Fig. 3F),
suggesting that either lack of Gal1 or of its N-glycosylated ligands
could favor recruitment of effector T cells to the target tissue. Thus,
Gal1 deficiency facilitates development of an autoimmune in-
flammatory process in the salivary gland characterized by increased
infiltration of IL-2- and IFN-γ–producing PD-1+CD8+ T cells that
confront a tissue microenvironment with reduced expression of the
inhibitory ligand PD-L1.
Sustained Gal1 Deficiency Interrupts DC-Mediated Regulatory
Circuits. Seeking possible mechanisms underlying enhanced CD8+
T-cell effector functions in response to Gal1 deficiency, we an-
alyzed the presence and phenotype of antigen-presenting cells
in SLNs. Surprisingly, we found that aged Lgals1−/− mice show
a reduced number of CD11c+ DCs in SLN when compared to
aged WT mice (Fig. 4A). However, these cells showed a
CD11chiLy6C−GR1−CD19−CD8−CD11b+ phenotype and exhibi-
ted higher CD86, CD40, and MHC II expression in comparison to
DCs from control mice (Fig. 4B). Thus, despite their reduced

























































































































































































































Fig. 1. Aged Lgals1−/− mice develop spontaneous sialadenitis. (A and B) Quantitative and qualitative detection of autoantibodies in sera from aged Lgals1−/−
and WT mice. (A) ELISA of anti-dsDNA, anti-ANA, and anti-SSA in serum samples from aged mice (mean ± SEM, n = 6). (B, Left) Indirect immunofluorescence
on HEp-2 cells exposed to serum from aged mice (representative results from five independent experiments with n = 3 per experiment). (B, Right) Quan-
tification of anti-nuclear IgG (mean ± SEM). (C–E) Analysis of submandibular salivary glands from aged (≥9 mo) Lgals1−/− and WT mice. (Left) Representative
images of salivary gland tissue sections (hematoxylin); (Right) inflammatory score determined as described in Materials and Methods (n = 8; C). Weight
(mean ± SEM, n = 8; D) and number of ducts per square millimeter (mean ± SEM, n = 5; E, Left, representative H&E images; E, Right, quantification) of
submandibular salivary glands. (F) Inflammatory infiltrates in salivary glands of aged Lgals1−/− and WT mice determined by flow cytometry. (Upper) Rep-
resentative dot plots showing gating strategies used to quantify the frequency of CD45+, CD3+CD8+, CD3+CD4+, and B220+ cells. The value shown in the
graph represents the percentage of infiltrating cells with respect to the whole salivary gland cells. (Lower) The average percentage of infiltrating cell
populations of the whole salivary gland (mean ± SEM, n = 16). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, Student’s t test.























aged Gal1-null mutant mice. To evaluate the functional capacity
of these cells, we cocultured DCs from aged Lgals1−/− or WTmice
with purified CD4+ and CD8+ T cells from young WT mice. Al-
though aged Lgals1−/− and WT DCs showed a comparable ca-
pacity of inducing CD8+ and CD4+ T-cell proliferation (Fig. 4C),
Lgals1−/−CD11c+ cells induced a bias toward a proinflammatory
CD4+ T-cell profile characterized by higher IFN-γ and lower IL-
10 synthesis compared to that triggered by WT DCs (Fig. 4D).
However, we found no significant differences in cytokine production
by CD8+ T cells in coculture experiments with aged CD11c+ cells
(Fig. 4E). We next evaluated the ability of CD11c+ cells to pro-
mote differentiation of Tregs. Notably, aged Lgals1−/− DCs were
less effective in promoting differentiation of CD4+CD25+Foxp3+
T cells compared to their WT counterpart (Fig. 4F). Accord-
ingly, aged Lgals1−/− mice showed a reduced percentage of
CD4+CD25+Foxp3+ and CD4+CTLA-4+ cells in SLN as compared
to WT mice (Fig. 4G). Thus, although CD11c+ cells from aged
Lgals1−/− mice did not differ from WT CD11c+ cells in their ca-
pacity to induce T-cell proliferation, these cells displayed a lower
ability to sustain tolerogenic microenvironments.
Given that salivary gland and lymph nodes from aged Lgals1−/−
mice display heightened CD8+ T-cell effector function, we asked
whether enhanced DC immunogenicity, leading to CD4+ T-cell
activation, may contribute to CD8+ T-cell activity. Remarkably,
cells and conditioned media obtained from cocultures of DCs and
CD4+ T cells supported a greater replication of CD8+ T cells
when CD11c+ cells were obtained from aged Lgals1−/− mice (Fig.
4H). Thus, Gal1-deficient CD11c+ DCs display greater immuno-
genic potential with enhanced T-cell activation properties and
reduced capacity to induce Treg cell differentiation.
Gal1 Limits the Severity of Experimental Autoimmune Sialadenitis.
To evaluate if variations of endogenous Gal1 synthesis might
contribute to the development of autoimmunity in exocrine glands,
we analyzed Gal1 expression in salivary glands and serum from
nonobese diabetic (NOD) mice, a mouse strain prone to the de-
velopment of autoimmune sialadenitis and a widely accepted
model of Sjögren’s syndrome. We found that Gal1 expression
decreased with age in serum and salivary glands from NOD mice
(Fig. 5 A and B). Interestingly, this reduction was not observed
in BALB/c mice, which did not develop spontaneous autoim-
munity (Fig. 5 C and D). To rescue the autoimmune phenotype,
we treated 16-wk-old NOD mice with recombinant Gal1 (rGal1).
Administration of rGal1 every 2 d for 2 wk effectively reduced the
magnitude of the inflammatory infiltrate in salivary glands, as
evidenced by a significant decrease in the frequency of CD45+ and
CD4+ cells and a tendency toward a decline in CD8+ and CD19+
populations (Fig. 5G). Thus, the autoimmune phenotype character-
ized by reduced Gal1 expression in aged NODmice can be alleviated
by administration of the exogenous recombinant protein.
Lower Gal1 Expression Correlates with Increased CD8+ T-Cell
Infiltration in Biopsies from Sjögren’s Syndrome Patients. To de-
termine the clinical relevance of our findings, we analyzed Gal1
expression in labial biopsies of pSS patients and control subjects
(biopsies of individuals with normal labial salivary glands; Table
1). Expression of Gal1 was identified in interstitial areas between
acini and ducts of the salivary gland from patients and controls
(Fig. 6 A, Left). Interestingly, biopsies from pSS patients (score
IV) showed reduced Gal1+ areas as compared to control samples
(Fig. 6 A, Right). Finally, we analyzed the frequency of CD8+,
CD20+, and CD4+ cell populations in samples from pSS patients.
We found a significant negative linear correlation between Gal1+
areas and the number of infiltrating CD8+ T cells (Fig. 6 B and
E), whereas no significant association was found with the number
of CD20+ or CD4+ cells (Fig. 6 C, D, F, and G). Thus, a reduction
in Gal1 expression in pSS could account in part for the inflam-
matory process in salivary glands, suggesting the involvement of
this glycan-binding protein in the etiopathogenesis of pSS and
highlighting the clinical relevance of our findings.
Discussion
Immune tolerance therapies, including those involving expansion
and/or differentiation of tolerogenic DCs and Tregs or amplifi-
cation of regulatory cytokines, are designed to reprogram immune
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Fig. 2. Interruption of complex N-glycan branching leads to the development of spontaneous sialadenitis. (A–C) Analysis of sialadenitis in aged (9 mo)
Mgat5−/− and WT mice. (Left) Representative images of salivary gland tissue sections and (Right) inflammatory score (mean ± SEM, n = 5; A), weight (mean ±
SEM, n = 8; B), and number of ducts per square millimeter (mean ± SEM, n = 5; C) of submandibular salivary glands. (D) Quantification by flow cytometry of
the average percentage of infiltrating cell populations of the whole salivary gland of aged (9 mo)Mgat5−/− andWTmice (mean ± SEM, n = 8). *P < 0.05; **P <
0.01; ***P < 0.001, Student’s t test.











































need for generalized immunosuppression (39). We and others
have previously shown that glycosylation-dependent Gal1-driven
regulatory circuits govern the fate of Th1 and Th17 effector cells
(14), promote differentiation of tolerogenic DCs (26, 40), favor
polarization of M2 proresolving macrophages and microglia (28,
29, 41), and foster the immunosuppressive activity of Tregs (20,
42, 43). This places Gal1 as an attractive target for the manage-
ment of a wide range of chronic T-cell–mediated autoimmune
diseases.
In this study, we report a central role for endogenous Gal1 as a
key immune regulator that promotes immune tolerance and pre-
vents age-dependent spontaneous autoimmunity. The effects of
aging in the immune system are widespread and include alter-
ations in immune cell development, activation, and differentiation,
leading to impairment of antimicrobial and antitumoral immunity
and increased susceptibility to autoimmune inflammation (44).
Here we found that aged Lgals1−/− mice develop a spontaneous
inflammatory disorder similar to Sjögren’s syndrome, character-
ized by increased frequency and activity of CD8+ T cells in lymph
nodes and salivary glands.
Studies of immune cell development revealed age-related changes
on hematopoietic stem cells, leading to contraction of the lym-
phoid cell compartment and amplification of myeloid cell pro-
grams in both mouse and human (45, 46). We found that Gal1
deficiency increases the frequency of CD8+ T cells in peripheral
lymph nodes during aging. Moreover, lack of Gal1 prevents ex-
pansion of the myeloid cell compartment as reflected by the re-
duced percentage of CD11c+ DCs. Hence, inhibition of Gal1
expression recapitulates the young immune phenotype with regard
to modulation of lymphoid and myeloid cell compartments.
However, despite the lower number of CD11c+ DCs in draining
lymph nodes of aged Lgals1−/− mice, these cells displayed a more
prominent mature phenotype and a greater capacity to induce
IFN-γ−mediated responses. Thus, Gal1 deficiency reinforces DC
immunogenicity, leading to exuberant tissue-specific autoimmune
reactions.
Galectins recognize LacNAc residues in a variety of glyco-
conjugates containing complex N-glycans and extended O-glycans
(47). In particular, the Mgat5 glycosyltransferase synthesizes the
β1,6-N-acetylglucosamine branch of complex N-glycans, allowing
elongation of repeated LacNAc residues (48). In pioneer studies,
Demetriou and colleagues showed that Mgat5 deficiency increases
T-cell activation and favors exacerbated immune responses. Ac-
cordingly,Mgat5−/− mice showed increased frequency of leukocyte
colonies in the kidney compatible with autoimmune glomerulo-
nephritis (49). The proposed mechanisms involved reduced
binding of Gal3 to T-cell surface glycoproteins, which lowered the
threshold of T-cell activation by enhancing T-cell receptor (TCR)
clustering (49). In addition, recent studies revealed that metabolic
supplementation of mucosal T cells from inflammatory bowel
disease patients with N-acetylglucosamine led to increased
branched N-glycosylation and inhibition of Th1 and Th17 patho-
genic responses (50). Moreover, in mouse models of autoimmune
encephalomyelitis and inflammatory bowel disease, Mgat5 de-
ficiency led to increased clinical severity and T-cell–mediated










































































































































































































Fig. 3. Gal1 deficiency enhances CD8+ T-cell function in salivary glands. (A) Cytokine production by salivary gland-infiltrating CD8+ T cells from aged Lgals1−/−
and WT mice (9 mo). (Left) Representative dot plots and (Right) percentage of IFN-γ+, IL-2+, or IFN-γ+IL-2+ CD8+ T cell populations (mean ± SEM, n = 8). (B)
Frequency of CD8+PD-1+ cells on salivary glands of aged (9 mo) Lgals1−/− and WT mice (mean ± SEM, n = 8; C). PD-L1 expression on salivary gland cells from
aged Lgals1−/− and WT mice (9 mo; mean ± SEM; n = 8). (Right) Mean fluorescence intensity (MFI) and (Left) representative histogram. (D) Expression of Cxcl10
and Cxcl9 mRNA by RT-qPCR in salivary glands from aged Lgals1−/− and WT mice (9 mo; n = 10). Results are expressed relative to Gapdh mRNA expression.
(E and F) Quantification of the frequency of CD8+ and CD8+CXCR3+ T cells in the submandibular lymph nodes (SLNs) of aged Lgals1−/−,Mgat5−/−, andWT mice
(9 mo). Comparison between Lgals1−/− and WT mice (mean ± SEM, n = 16; E) and between Mgat5−/− and WT mice (mean ± SEM, n = 8; F). *P < 0.05; **P <
0.01; ns, nonsignificant; Student’s t test.























Interestingly, our study provides a direct comparison of the phe-
notypes of Lgals1−/− andMgat5−/−mice, indicating that both strains
develop spontaneous autoimmune sialadenitis. Thus, Gal1 inter-
actions with complex branched N-glycans may function as an immune
rheostat that prevents age-dependent spontaneous autoimmunity.
However, as compared to Lgals1−/−, mice lacking Mgat5 display
augmented infiltration of all immune cell populations. These ob-
servations suggest that additional galectins, including Gal3 and
Gal8, may contribute to immune cell homeostasis by interacting
with β1,6-branched N-glycans (49, 52). Interestingly, an age-
dependent autoimmune phenotype was also observed in mice
lacking other endogenous lectins including Siglec-G, a sialic acid-
binding lectin, deficiency of which led to elevated autoantibody
levels and mild glomerulonephritis (53), and Gal3, absence of
which led to a lupus-like disease by promoting spontaneous ger-
minal center formation and autoantibody production (54). Fur-
thermore, loss of liver α2,6-sialyltransferase (ST6Gal1), an enzyme
required for α2,6-linked sialylation which prevents Gal1 binding,
elicits fatty liver disease characterized by age-dependent buildup
of fatty acid droplets and a proinflammatory phenotype involving
polarization of M1-type macrophages (55). Altogether, these ob-
servations suggest a broader role of endogenous glycan-binding
proteins and their glycosylated ligands in supporting immune tol-
erance in the context of immunological senescence.
In the present study, we found that Gal1 deficiency impacts
immune responses by increasing infiltration of a population of
activated CD8+PD-1+ T cells in salivary glands and impairing
local PD-L1 expression. Further studies should be aimed at ex-
amining whether Gal1 directly controls PD-L1 expression on the
surface of glandular cells via transcriptional or posttranslational
mechanisms or whether this lectin indirectly shapes the local
inflammatory response to modulate PD-L1 expression. Accordingly,
in tumors, PD-L1 expression can be classified as constitutive or
inducible upon T-cell infiltration and IFN-γ production (56, 57).
Moreover, PD-L1 expression is increased after IFN-γ exposure in
salivary epithelial cells and biopsies of patients with Sjögren’s
syndrome (58). In our experiments, aged Lgals1−/− mice displayed
a reduced surface expression of PD-L1 despite exhibiting in-
creased infiltration of CD8+IFN-γ+ cells. Interestingly, both mouse
and human PD-L1 have several conserved sites for N-glycosylation,
and these glycan structures are required for PD-L1 stability on the
cell surface since nonglycosylated PD-L1 has increased turnover
rate and degradation as compared to glycosylated forms (59).
Regarding our findings, we might hypothesize that interruption of
Gal1–N-glycan interactions could reduce cell surface retention of
PD-L1, as has been described for the TCR and CTLA-4 (60, 61).
Hence, the apparent contradiction of reduced PD-L1 expression
in an IFN-γ−enriched microenvironment could be explained by
the reduced stability and/or surface retention of PD-L1 due to the
absence of galectin–glycan interactions.
Currently, pSS patients are treated with drugs that relieve
symptoms, mainly tears and saliva substitutes, topical therapies,
sialogogues, and analgesics (62). Systemic therapeutic modalities
based on biological products targeting proinflammatory cytokines,
antigen presentation, and immune cell activation are currently
under study, although with limited results (62, 63). Here, we pro-
vide evidence that Gal1 expression is down-regulated during the
development of Sjögren’s syndrome-like disease in NOD mice and
is reduced in gland samples of pSS patients. Moreover, we found a
negative linear association between Gal1+ tissue and local infil-
tration of CD8+ T cells, suggesting that loss of Gal1 may contribute
to CD8+ T-cell expansion, recruitment, and amplification of their
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Fig. 4. Gal1 deficiency impairs the tolerogenic capacity of dendritic cells (DCs). (A and B) Frequency and phenotypic analysis of CD11c+ cells in submandibular
lymph nodes (SLNs) of aged (9 mo) Lgals1−/− and WT mice. Percentage of CD11c+ cells (mean ± SEM, n = 8; A). Expression of CD86, CD80, CD40, and MHC II
measured as mean fluorescence intensity (MFI; mean ± SEM, n = 8; B). (C–E) Cocultures of CD11c+ cells obtained from aged Lgals1−/− or WT mice with CD8+ or
CD4+ T cells from young WT mice in the presence of an anti-CD3 monoclonal antibody. Representative histograms of CD8 (Left) or CD4 (Right) T-cell pro-
liferation of five independent experiments with n = 4 are shown (C). Secretion of IFN-γ and IL-10 in CD11c+:CD4+ (D) and CD11c+:CD8+ (E) culture super-
natants (n = 7, mean ± SEM). Frequency of regulatory T cells (Tregs) in CD11c+:CD4+ cocultures (n = 7, mean ± SEM; F). (G) Percentage of CD4+CD25+Foxp3+
Tregs and CD4+CTLA-4+ cells in submandibular lymph nodes (SLNs) of aged (9 mo) Lgals1−/− and WT mice (n = 16, mean ± SEM). (H) Proliferation of CD8+
T cells cultured in the presence of cells and conditioned medium from CD11c+:CD4+ cocultures using Lgals1−/− or WT CD11c+ cells. (Left) Representative
histograms of CD8+ T-cell proliferation measured by CFDA-SE dilution. (Right) Proliferation index and replication index (n = 4, mean ± SEM; representative
results of three independent experiments are shown). *P < 0.05; ns, nonsignificant; Student’s t test.











































Autoantibodies, in addition to autoreactive T cells, play a
central role in the pathogenesis of many autoimmune diseases,
including rheumatoid arthritis, Sjögren’s syndrome, and SLE. In
our study, we observed increased serum levels of anti-dsDNA,
anti-nuclear, and anti-Ro/SSA antibodies in aged Lgals1−/− mice.
These results emphasize the broader role of Gal1–N-glycan in-
teractions in suppressing autoimmune inflammation, consistent
with previous studies reporting the ability of rGal1 to inhibit
production of anti-dsDNA autoantibodies and reducing pro-
teinuria in experimental lupus-like disease (NZBxNZWmice) (31).
Interestingly, aged Lgals1−/− mice of the 129S/V background had a
significant increase in anti-dsDNA autoantibodies (31). Here we
show that Gal1 deficiency promotes the emergence of autoanti-
bodies that could be involved in both Sjögren’s syndrome and
lupus-like diseases; however, in our experimental conditions, we
found no overt kidney damage in aged Lgals1−/− mice (SI Ap-
pendix, Fig. S1), suggesting that genetic background and envi-
ronmental factors may determine the clinical outcome of different
autoimmune diseases. Finally, we demonstrate that administration
of rGal1 to NOD mice with compromised salivary gland auto-
immunity attenuates immune cell infiltration. Given the limita-
tions encountered in treatment of this complex autoimmune
disease and the urgent need for more selective therapies, Gal1-
based immunomodulatory drugs may be effective either alone or
in combination to reduce disease severity and improve life quality
of pSS patients.
Materials and Methods
Mouse. Lgals1−/− mice were originally provided by Francoise Poirier (Institut


























































































































































































   
Fig. 5. Age-dependent reduction of Gal1 expression in autoimmune-prone NODmice. (A–D) Determination of Gal1 expression in serum and salivary glands of NOD
and BALB/c mice (6 to 10, 12 to 16, and 18 to 22 wk old). ELISA for Gal1 in serum samples of NOD (A) and BALB/c (C) mice (n = 5 per group) and RT-qPCR analysis of
Gal1 expression in submandibular salivary glands (n = 4 per group) from NOD (B) and BALB/c (D) mice (*P < 0.05; **P < 0.01, Student’s t test). (E) Frequency of
infiltrating CD45+, CD4+, CD8+, and CD19+ cells in submandibular salivary glands of NOD (16 wk old) mice treated with rGal1 (100 μg) or PBS (six injections every 2 d).
(Upper) Representative dot plots showing gating strategies used to quantify the frequency of CD45+, CD4+, CD8+, and CD19+ cells; the value shown on the graph
represents the percent value of infiltrating cells with respect to whole salivary gland cells. (Lower) The average percentage of infiltrating cell populations with respect
to the whole salivary gland (mean ± SEM, n = 5). A representative of three independent experiments is shown (*P < 0.05, Mann–Whitney test).
Table 1. Characteristics and clinical features of patients with
primary Sjögren’s syndrome (pSS) and control subjects
Characteristic pSS patients Control subjects
No. of patients 19 14
Inflammatory score III/IV 0
Sex 15 (F); 4 (M) 12 (F); 2 (M)
Age, y 52 ± 8 43 ± 11



























were provided by The Jackson Laboratory. Animals (female mice) were bred
at the animal facilities of the Institute of Biology and Experimental Medicine
and the School of Exact and Natural Sciences (University of Buenos Aires)
according to National Institutes of Health guidelines. This included ages 8 to
12 wk (young C57BL/6 WT mice), ≥9 mo (aged Lgals1−/−, Mgat5−/−, and
C57BL/6 WT mice), and 6 to 22 wk (NOD and BALB/c mice). All experimental
procedures were reviewed and approved by the institutional animal care
and use committee.
ELISA. Measurements of anti-dsDNA, anti-ANA, and anti-SSA/Ro60 were
performed according to themanufacturer’s instructions (Alpha Diagnostic) in
serum samples of Lgals1−/− and WT mice. Mouse IFN-γ and IL-10 were de-
termined in culture supernatants using a DuoSet enzyme-linked immuno-
sorbent assay (ELISA) kit (R&D Systems) and an ELISA set (BD OptEIA),
respectively. Soluble Gal1 was determined in serum samples of NOD and WT
mice using an in-house ELISA as previously described (64). In brief, high-
binding 96-well microplates (Costar; Corning) were coated with purified
rabbit anti-mouse Gal1 polyclonal IgG (2 μg/mL), blocked with 2% BSA in
PBS, detected with biotinylated anti-Gal1 polyclonal IgG (100 ng/mL), and
revealed using 0.1 mg/mL tetramethylbenzidine and 0.06% H2O2 in citrate
phosphate buffer, pH 5.0. Optical densities were determined at 450 nm and
550 nm in a Multiskan MS microplate reader (Thermo Fisher Scientific). A
standard curve ranging from 2.5 to 160 ng/mL rGal1 was run in parallel.
Indirect Immunofluorescence in HEp-2 Cells. Autoantibodies were detected
using an adapted protocol of indirect immunofluorescence in HEp-2 cells
(BioSystems). Briefly, diluted serum samples (1:80) were incubated with ad-
herent HEp-2 cells (n = 6 wells per slide). After 30 min incubation, slides were
washed and incubated with Alexa Fluor 488-conjugated anti-mouse IgG
(1:1,000; Cell Signaling) and Evans blue counterstain (Sigma Diagnostics) for
an additional 30 min. Examination was performed using confocal microscopy
(Fluoview10i; Olympus). The pattern was determined according to the
manufacturer’s instructions. The nuclear green fluorescence intensity was
quantified using ImageJ program (v1.64).
Histopathology. Submandibular glands as well as other organs (kidney, skin,
stomach, retina, thyroid, pancreas, liver, and uterus) were fixed in 4% para-
formaldehyde and embedded in paraffin. Tissue sections stained with hema-
toxylin–eosin were used for histopathological assessment. The inflammatory









































































































Fig. 6. Dysregulated Gal1 expression in salivary glands from primary Sjögren’s syndrome patients. (A) Detection of Gal1 by immunohistochemistry in labial
biopsies from pSS patients and control individuals (suspected sialadenitis with negative biopsies; score 0). (Left) Representative images used to quantify the
Gal1+ area. (Right) Quantification (mean ± SEM of Gal1+ area; *P < 0.05, Student’s t test). (B–D) Immunohistochemical analysis of CD8+, CD20+, and CD4+ cells
in labial biopsies of pSS patients. (E–G) Linear regression between Gal1+ area and the number of CD8+ (E), CD20+ (F), and CD4+ (G); n = 19; *P < 0.05, linear
regression.











































diagnosis criteria established by Chisholm and Mason (38). In brief, grade 0,
without infiltrate; grade I, mild diffuse lymphocytic/plasmacytic infiltrate;
grade II, moderate infiltrate or less than one focus of 50 mononuclear cells per
4 mm2; grade III, one focus of 50 mononuclear cells per 4 mm2; grade IV, more
than one focus of 50 mononuclear cells per 4 mm2. The number of ducts per
area was determined by counting four random fields per gland using 40×
images and the ImageJ program (v1.64).
Cell Suspensions and Flow Cytometry. Cell suspensions from submandibular
glands were generated using a gentleMACS Dissociator (Miltenyi Biotec).
Lymph node and spleen cell suspensions were obtained by mechanic disruption.
Red blood cells were lysed and all suspensions filtered. Cell surface staining was
performed using several combinations of antibodies: PE-conjugated anti-CD45,
PE-conjugated anti-CD8, FITC-conjugated anti-CD3, APC-conjugated anti-CD4,
APC-conjugated anti-CD45R (B220), PE-conjugated anti-CD11c, APC-conjugated
anti-CXCR3, FITC-conjugated anti-CD8, PercP-Cy5,5-conjugated anti–PD-1, PE-
conjugated anti–PD-L1, APC-conjugated anti–CTLA-4, PE-conjugated anti-CD86,
PE-conjugated anti-MHC II, FITC-conjugated anti-CD4, PE-conjugated anti-CD25,
PECy7-conjugated anti-CD19 (all from BD Biosciences), FITC-conjugated anti-
CD80 (Biolegend) and FITC-conjugated anti-CD40 (Novus Biologicals). Fre-
quency of Tregs was determined using the mouse Treg staining kit (eBioscience)
and the antibody APC-conjugated anti-mouse Foxp3 (BD Biosciences). For de-
termination of intracellular cytokines, cells were cultured with ionomycin
(750 ng/mL; Sigma) and PMA (50 ng/mL; Sigma) for 5 h. GolgiStop (BD Bio-
sciences) was added after 1 h. Cell surface staining was performed before
fixation and permeabilization using BD Cytofix/Cytoperm (BD Biosciences).
Intracellular staining was performed with FITC-conjugated anti–IFN-γ and
PeCy7-conjugated anti–IL-2 (BD Biosciences). Samples were analyzed on a
FACSCanto (BD Biosciences) with FlowJo software (v7.6.5).
Real-Time Quantitative RT-PCR. RNA was obtained using TRIzol reagent
according to the manufacturer’s instructions. DNA contamination was removed
using DNase I. cDNA was synthesized using SuperScript III Reverse Transcriptase
(Invitrogen). For real-time PCR, the SYBR Green PCR Master Mix was used with
an ABI System 7500 (Applied Biosystem). Primers are as follows: Lgals1 5′-
TCAGCCTGGTCAAAGGTGAT-3′ 5′-TGAACCTGGGAAAAGACAGC-3′, Cxcl10 5′-
ATGACGGGCCAGTGAGAATG-3′ 5′-TCGTGGCAATGATCTCAACAC-3′, Cxcl9 5′-
TCGGACTTCACTCCAACACAG-3′ 5′-AGGGTTCCTCGAACTCCACA-3′, and Gapdh
5′-CAGAACATCATCCCTGCAT-3′ 5′-GTTCAGCTCTGGGATGACCTT-3′. Quantifica-
tion was performed as an absolute value using Gapdh as a housekeeping gene.
Coculture of DCs and T Cells. CD4+ and CD8+ T lymphocytes from 8- to 12-wk-
old WT mice were isolated using Dynabeads untouched Mouse CD4 cells kit
and Dynabeads untouched mouse CD8 cells kit (both from Invitrogen), re-
spectively. CD11c+ cells of 9-mo-old Lgals1−/− or WT mice were purified by cell
sorting using a FACSAria II (BD Biosciences) or using mouse CD11c microbeads
(Miltenyi Biotec). Cocultures of CD4+:CD11c+ cells and CD8+:CD11c+ cells (10:1)
were performed in RPMI 10% serum (Gibco) and antibiotic-antimycotic (Gibco)
with soluble purified NA/LE anti-mouse CD3e (1 μg/mL; BD Biosciences) in 96-
well U-plates for 96 h. In another set of experiments, 1 × 105 cells from the
CD4+:CD11c+ cocultures were taken and incubated with 1 × 105 CD8+ T cells
in the presence of CD4+:CD11c+ conditioned medium (1:1), soluble purified
NA/LE anti-mouse CD3e (1 μg/mL; BD Biosciences), and purified NA/LE anti-
mouse CD28 (2 μg/mL; BD Biosciences) antibodies for 72 h.
Proliferation Assay. Purified CD4+ and CD8+ cells were labeled using Vybrant
CFDA-SE cell tracer kit (Molecular Probes) before coculture experiments.
Briefly, cells were washed with PBS and incubated with CFDA-SE (1.5 μM) for
7 min at 37 °C. Proliferation was analyzed on a FACSCanto (BD Biosciences)
using the proliferation tool of FlowJo software (v7.6.5), obtaining pro-
liferation and replication indexes.
Labial Biopsies of pSS Patients. Human paraffin-embedded labial biopsies of
patients with pSS (inflammatory score III/IV) and controls (suspected sialadenitis
with negative biopsies; score 0) were provided by the Rheumatology Unit from
Hospital Bernardino Rivadavia (Buenos Aires, Argentina). Complementary in-
formation is shown in Table 1. Samples were obtained following patients’
informed consent, and protocols were approved by the ethics committee of
Hospital Rivadavia.
Immunohistochemistry. Sections from labial biopsy samples (5 μm) were
dewaxed and rehydrated in serial ethanol dilutions. Endogenous peroxidase
activity was blocked with 3% H2O2. Antigen retrieval was performed with
sodium citrate treatment (0.01 M; pH 6.0), and nonspecific antigens were
blocked with horse serum. Slides were stained with anti-human Gal1, anti-
human CD8, anti-human CD4, and anti-human CD20 antibodies. Primary
antibodies (1:100; Abcam) were incubated overnight and detected using the
Vectastain ELITE ABC kit (Vector Lab). Micrographs were taken with an
Olympus CX31 microscope and analyzed using ImageJ software (v1.64).
Treatment with rGal1. Sixteen-week-old NOD mice were treated with rGal1
(100 μg per mouse; i.p.) or PBS three times a week for 2 wk as described (16).
Animals were euthanized, salivary glands processed, and cell suspensions
were stained and revealed by flow cytometry as previously described.
Statistical Analysis. Prism 5.0 software (GraphPad) was used for statistical
analysis. Two groups were comparedwith the Student’s t test orMann–Whitney
test for unpaired data, and lineal relations were tested with lineal regression
statistics. P values of 0.05 or less were considered significant.
Data Availability. All data, associated protocols, and materials used for this
study are available within the manuscript and SI Appendix.
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